Advances in Psoriasis Treatment: Emerging Therapies and Future Directions
The psoriasis research pipeline is rich with new medications as well as new ways to use existing therapies, according to Dr. Anthony Fernandez, director of medical and inpatient dermatology at the Cleveland Clinic. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Fernandez, who outlined three therapeutic areas he’s most excited about in the treatment of p …
The psoriasis research pipeline is rich with new medications as well as new ways to use existing therapies, according to Dr. Anthony Fernandez, director of medical and inpatient dermatology at the Cleveland Clinic. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Fernandez, who outlined three therapeutic areas he’s most excited about in the treatment of p … Continue reading "Advances in Psoriasis Treatment: Emerging Therapies and Future Directions"
NBC News was one of the media outlets who covered the Marines’ recent tightening of shaving waivers, which could negatively impact the careers of Marines with pseudofolliculitis barbae (PFB). Under a 2022 policy, Marines with treatment-resistant PFB could receive temporary or permanent shaving waivers. Now, Marines with PFB could be separated from the branch if their PFB does not improve within … 
Leslie Rank, PhD, Global Product Development Lead of Facial Treatment Products, and Rachel Bechtel, Senior Scientist on the Facial Cleansing Product & Process Innovation Team at Kenvue, spoke to dermatology residents at The George Washington University’s first Lab to Label Conference, about the formulation of popular products including dark spot actives, vitamin A derivatives, and cleansers. … 
Welcome to another installment of "From the JDD Podcast Vault" series! This week, we’re digging into a truly cautionary tale with the episode: Thin Skinned: Topical Steroid Safety and Legal Landmines, hosted by Dr. Adam Friedman and featuring the ever-insightful Dr. Raj Chovatiya.
“Just put some salve on it.” Sounds harmless enough, right? But let’s pause and ask — what could possibl … 
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo …